Valuation: Whitehawk Therapeutics, Inc.

Market Cap 165M 146M 136M 124M 233M 15.64B 237M 1.63B 640M 8.16B 618M 605M 26.01B P/E 2026 *
-3.14x
P/E 2027 * -3.23x
Enterprise Value 165M 146M 136M 124M 233M 15.64B 237M 1.63B 640M 8.16B 618M 605M 26.01B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
87.38%
Yield 2026 *
-
Yield 2027 * -
1 day-4.93%
1 week-17.90%
Current month-23.14%
1 month-29.17%
3 months-25.71%
6 months-29.68%
Current year+19.42%
1 week 2.87
Extreme 2.87
3.57
1 month 2.87
Extreme 2.87
4.2
Current year 2.36
Extreme 2.36
5.5
1 year 1.97
Extreme 1.97
5.5
3 years 1.21
Extreme 1.21
5.7
5 years 1.21
Extreme 1.21
32.5
10 years 1.21
Extreme 1.21
32.99
Manager TitleAgeSince
Chief Executive Officer 55 2023-10-01
Chief Executive Officer 55 2023-03-02
Chief Tech/Sci/R&D Officer 69 2025-11-30
Director TitleAgeSince
Chairman 61 2022-12-31
Chairman 55 2017-02-28
Director/Board Member 54 2021-08-25
Date Insider Type Main position Quantity % Market Cap. Importance
9/15/26 Free

Chief Technology Officer

183,266 0.3889%
9/15/26 Free

Chief Executive Officer

387,914 0.8231%
9/15/26 Free

Chief Technology Officer

162,500 0.3448%
Change 5-day change 1-year change 3-year change Capi.($)
-4.93%-17.90%+30.77%-30.86% 165M
+0.43%+6.59%+56.57%+106.64% 1,120B
+0.90%-2.25%+32.26%+63.73% 616B
+0.71%+3.24%+24.33%+91.33% 504B
-0.13%+5.98%+33.66%+50.18% 367B
+0.52%+0.24%+72.13%+40.11% 360B
-0.95%+4.70%+19.65%+42.71% 288B
-1.98%+3.73%-0.89%+10.43% 258B
-0.35%+4.25%+44.74%+52.06% 234B
-0.75%+3.32%+27.18%+94.07% 194B
Average -0.65%+1.46%+34.04%+52.04% 394.11B
Weighted average by Cap. +0.13%+3.83%+39.34%+71.82%

Financials

2026 *2027 *
Net sales - -
Net income -76.17M -67.7M -62.75M -57.09M -108M -7.23B -109M -754M -296M -3.77B -286M -280M -12.03B -88.66M -78.81M -73.04M -66.46M -125M -8.41B -127M -878M -344M -4.39B -333M -326M -14B
Net Debt - -
Projected Income Statement - Annual - Whitehawk Therapeutics, Inc.
Logo Whitehawk Therapeutics, Inc.
Whitehawk Therapeutics, Inc., formerly Aadi Bioscience, Inc., is a preclinical stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Its advanced three-asset antibody drug conjugate (ADC) portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. Its assets include HWK-007, HWK-016 and HWK-206. HWK-007 represents a differentiated opportunity to potentially be among the first next-wave ADCs in clinical development for high PTK7-expressing cancers. HWK-016 is the first ADC that targets the membrane-bound portion of MUC16, a glycoprotein often overexpressed in cancers of female origin. HWK-016 is being evaluated in IND-enabling studies. HWK-206 is designed to address the neuronal target, SEZ6, which is often overexpressed in cancers of neuroendocrine origin.
Employees
32
Date Price Change Volume
26-10-16 US$2.890 -4.93% 273,975
26-10-15 US$3.040 +2.36% 337,395
26-10-14 US$2.970 -1.66% 510,063
26-10-13 US$3.020 -10.65% 461,731
26-10-12 US$3.380 -3.98% 222,054
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Whitehawk Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
2.890USD
Average target price
7.714USD
Spread / Average Target
+166.93%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Whitehawk Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. WHWK Stock